|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||468.36 - 489.21|
|52-week range||383.12 - 553.29|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||25.80|
|Forward dividend & yield||5.80 (1.18%)|
|Ex-dividend date||11 Mar 2022|
|1y target est||N/A|
Through the first JV, Humana (HUM) and its partner are pumping $800 million into developing 67 facilities by early 2023.
Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.
The launch of QIAstat-Dx Rise and other advancements to the QIAstat-Dx portfolio are expected to strengthen QIAGEN's (QGEN) syndromic testing solutions.